ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EKF.GB EKF Diagnostics Holdings PLC

25.00
-0.50 (-1.96%)
13 Dec 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
EKF Diagnostics Holdings PLC AQSE:EKF.GB Aquis Stock Exchange Ordinary Share GB0031509804 Ordinary Shares 1p
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.96% 25.00 23.00 34.00 28.50 24.73 25.50 86,817 15:29:42
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

EKF Diagnostics Holdings PLC Change of Adviser (6541L)

09/01/2023 7:00am

UK Regulatory


EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more EKF Diagnostics Charts.

TIDMEKF

RNS Number : 6541L

EKF Diagnostics Holdings PLC

09 January 2023

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Change of Adviser

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , announces Singer Capital Markets as sole broker to the Company. Singer Capital Markets also continues to act as Nominated Adviser.

 
EKF Diagnostics Holdings plc                                       www.ekfdiagnostics.com 
Mike Salter, CEO / Marc Davies, CFO                              Tel: +44 (0)29 2071 0570 
 
Singer Capital Markets (Nominated Adviser                        Tel: +44 (0)20 7496 3000 
 & Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Walbrook PR Limited                        Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth                           Mob: +44 (0)7980 541 893 / +44 
                                                                          (0)7584 391 303 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers and 
                           consumables, particularly for use in the area of Hematology 
                           and Diabetes, for use in hospital and research laboratories, 
                           doctor's offices, blood banks and for in-field anaemia 
                           screening programmes. EKF has an estimated 80,000 
                           hemoglobin, hematocrit, HbA1c, glucose and lactate 
                           analysers in regular use across more than 100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                           Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated 
                           Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                           labelling, Molecular and forensic kits 
 Laboratory Testing       Laboratory testing services certified under the Clinical 
                           Laboratory Improvement Amendments ("CLIA") for high 
                           complexity testing. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPDZGGMLDNGFZG

(END) Dow Jones Newswires

January 09, 2023 02:00 ET (07:00 GMT)

1 Year EKF Diagnostics Chart

1 Year EKF Diagnostics Chart

1 Month EKF Diagnostics Chart

1 Month EKF Diagnostics Chart